Summary
- The U.S. Securities and Exchange Commission (SEC) announced that it has initiated a public comment process to review the approval of the Injective (INJ) Staking ETF.
- If approved, the ETF is expected to track the native asset INJ of the Injective blockchain and may be listed on the CBOE BZX Exchange.
- The SEC stated that it plans to make a final decision on the ETF approval after collecting opinions from investors and market participants.
On the 25th (local time), according to the crypto-specialized media outlet The Block, the U.S. Securities and Exchange Commission (SEC) has begun a public comment process to review whether to approve an Injective (INJ)-based staking exchange-traded fund (ETF).
If approved, the ETF will track Injective, the native asset of the Injective blockchain, and could be listed on the Cboe BZX Exchange, which is under the Chicago Board Options Exchange (CBOE).
The SEC plans to make a final decision on the ETF approval after collecting opinions from investors and market participants through this comment process.
JH Kim
reporter1@bloomingbit.ioHi, I'm a Bloomingbit reporter, bringing you the latest cryptocurrency news.
